These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 5030806)

  • 1. Effect of day of dosage omission on survival time in the regularly scheduled methotrexate (NSC-740) treatment of leukemia L1210.
    Straus MJ; Goldin A
    Cancer Chemother Rep; 1972 Feb; 56(1):25-30. PubMed ID: 5030806
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased lifespan using the priming dose schedule design in carbazilquinone (NSC-134679) treatment of mouse leukemia L1210.
    Straus MJ; Goldin A
    Cancer Chemother Rep; 1972 Feb; 56(1):19-23. PubMed ID: 5030804
    [No Abstract]   [Full Text] [Related]  

  • 3. Differential cell permeability and the basis for selective activity of methotrexate during therapy of the L1210 leukemia.
    Sirotnak FM; Donsbach RC
    Cancer Res; 1973 Jun; 33(6):1290-4. PubMed ID: 4718678
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
    Schmid FA; Hutchison DJ
    Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of combination treatment with adriamycin and methotrexate on the survival time of leukemic (L 1210) mice.
    Miyakawa A; Padarathsingh M; Vadlamudi S; Goldin A
    Chemotherapy; 1973; 19(1):38-46. PubMed ID: 4747574
    [No Abstract]   [Full Text] [Related]  

  • 6. Liposomal methotrexate in the treatment of murine L1210 leukemia.
    Woo SY; Dilliplane P; Rahman A; Sinks LF
    Cancer Drug Deliv; 1983; 1(1):59-62. PubMed ID: 6544118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo effects of methotrexate. Inhibition of DNA synthesis and cell death in sensitive and resistant L1210 ascites populations.
    Hofer KG
    Chemotherapy; 1972; 17(1):59-70. PubMed ID: 5009468
    [No Abstract]   [Full Text] [Related]  

  • 8. Dose-related synergism of cytosine arabinoside and methotrexate against murine leukemia L1210.
    Avery TL; Roberts D
    Eur J Cancer (1965); 1974 Jul; 10(7):425-9. PubMed ID: 4457345
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.
    Sirotnak FM; Moccio DM; Dorick DM
    Cancer Res; 1978 Feb; 38(2):345-53. PubMed ID: 304375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
    Kline I; Woodman RJ; Gang M; Cysyk RL; Venditti JM
    Cancer Chemother Rep; 1973; 57(3):291-8. PubMed ID: 4751255
    [No Abstract]   [Full Text] [Related]  

  • 11. New approaches to chemotherapy.
    Hutchison DJ
    Ann N Y Acad Sci; 1971 Nov; 186():496-500. PubMed ID: 5002440
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of the sequence of administration of cytoxan and methotrexate on the life-span of L1210 leukemic mice.
    Straus MJ; Mantel N; Goldin A
    Cancer Res; 1972 Feb; 32(2):200-7. PubMed ID: 5058180
    [No Abstract]   [Full Text] [Related]  

  • 13. Sustained-release methotrexate for intracavitary chemotherapy.
    Chatelut E; Suh P; Kim S
    J Pharm Sci; 1994 Mar; 83(3):429-32. PubMed ID: 8207696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC-409962) and methotrexate (NSC-740) as combination therapy for advanced mouse leukemia L1210.
    Venditti JM; Kline I; Tyrer DD; Goldin A
    Cancer Chemother Rep; 1965 Oct; 48():35-9. PubMed ID: 5834736
    [No Abstract]   [Full Text] [Related]  

  • 15. Antitumor activity of a water-insoluble compound entrapped in liposomes on L1210 leukemia in mice.
    Brassinne C; Atassi G; Frühling J; Penasse W; Coune A; Hildebrand J; Ruysschaert JM; Laduron C
    J Natl Cancer Inst; 1983 Jun; 70(6):1081-6. PubMed ID: 6574278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in L1210 leukemia.
    Wampler GL; Carter WH; Campbell ED; Goldman ID
    Cancer Treat Rep; 1987 Jun; 71(6):581-91. PubMed ID: 3581096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antileukemic effectiveness of 5-fluorouracil and methotrexate in the combination chemotherapy of advanced leukemia L1210 in mice.
    Kline I; Venditti JM; Mead JA; Tyrer DD; Goldin A
    Cancer Res; 1966 May; 26(5):848-52. PubMed ID: 5934795
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemotherapeutic effect of a water-oil-water emulsion of methotrexate on the mouse L1210 leukaemia.
    Elson LA; Mitchlev BC; Collings AJ; Schneider R
    Rev Eur Etud Clin Biol; 1970 Jan; 15(1):87-90. PubMed ID: 5442691
    [No Abstract]   [Full Text] [Related]  

  • 19. Identical efficacy of methotrexate regimens with N5-methyltetrahydrofolate rescue or with leucovorin rescue for treatment of L1210 murine leukemia.
    Nixon PF; Wilson L
    Cancer Treat Rep; 1983 Jan; 67(1):59-62. PubMed ID: 6604578
    [No Abstract]   [Full Text] [Related]  

  • 20. Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice.
    Warzocha K; Robak T
    Acta Haematol Pol; 1992; 23(1):55-62. PubMed ID: 1615753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.